Pfizer Surges on Encouraging Trial Results for Antiviral Covid-19 Pill
Investing.com
Published Nov 05, 2021 07:48AM ET
By Dhirendra Tripathi
Investing.com – Pfizer stock (NYSE:PFE) climbed 11% in Friday’s premarket trading after the pharma giant reported encouraging trial results for its antiviral pill against Covid-19.
Pfizer said that its drug, still under development, cuts the risk of severe disease by as much as 89%. There were no deaths reported in the trial group which received the drug rather than the placebo.
Pfizer’s results suggest it may be more effective than that of rival Merck (NYSE:MRK). Merck's oral antiviral medicine molnupiravir indicated it reduced the risk of hospitalization or death by half.
Molnupravir was approved for emergency use in the U.K. this week, its first authorization to date.
Pfizer said it will approach the Food and Drug Administration soonest for approval for emergency use.
The drug is given in combination with an older antiviral called ritonavir. The combination treatment, branded Paxlovid, consists of three pills given twice daily.
The company said adverse events happened in about 20% of both treatment and placebo patients and said most of them were mild in intensity.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.